Search Team

Search by Last Name
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 
Headshot

Jenny Shmuel, Ph.D.

Associate

Boston, MA
617-521-7045
shmuel@fr.com
Download vCard

Background

​Jenny Shmuel is an Associate in the Boston office of Fish & Richardson. She was a Summer Associate with the firm in 2011. Ms. Shmuel has worked on a range of intellectual property matters, including patent litigation in the software and medical device fields, copyright litigation, trade secret litigation in state court, and various patent and trademark prosecution projects.

Education

J.D., Harvard Law School 2012
cum laude


Ph.D., Massachusetts Institute of Technology 2009
Materials Science & Engineering


B.S., Massachusetts Institute of Technology 2004
Materials Science & Engineering

Memberships & Affiliations

​Women's Bar Association of Massachusetts​

Other Distinctions

Selected Publications

Shmuel, JA, Chamberlain, HC, and Francis, TM, "Amgen’s Humira Biosimilar Becomes the Fourth FDA Approved Biosimilar," Fish Litigation Blog, September 27, 2016.

Shmuel, JA, Chamberlain, HC, and Francis, TM, "Amgen Argues "Entire Balance of BPCIA" in Jeopardy unless Federal Circuit Discovery Ruling," Fish Litigation Blog, September 20, 2016.

Shmuel, JA, Orlady, WJ, and Francis, TM, "The Dance Continues: Apotex Petitions the Supreme Court for Review," Fish Litigiation Blog, September 19, 2016.

Shmuel, JA and Francis, TM, "Amgen Loses BPCIA Suit Against Apotex’s Neulasta® and Neupogen® Biosimilars​​," Fish Litigation Blog, September 8, 2016. 

Shmuel, JA and Francis, TM, "FDA Approves Sandoz’s Biosimilar of Enbrel®​," Fish Litigation Blog, August 31, 2016. 

Shmuel, JA, and Bandli, RM, "Court Invalidates Janssen Remicade® Patent for Double Patenting; Celltrion Seeks Speedy Appeal​," Fish Litigation Blog, August 25, 2016.

Shmuel, JA, "Federal Circuit Denies Motion to Dismiss Appeal of BPCIA-Related Discovery Order​​," Fish Litigation Blog, August 15, 2016. 

​Shmuel, JA, and Francis, TM, "Amgen Can Enforce Notice of Commercial Marketing for Epogen​® Biosimilar​," Fish Litigation Blog, August 8, 2016. 

Shmuel, JA, and Francis, TM, "Amgen DJ to Compel Patent Dance Dismissed ," Fish Litigation Blog, July 26, 2016.

Shmuel, JA, Francis, TM, and Pechette, AM, "Fall-Out from the Federal Circuit’s Decision in Amgen v. Apotex," Fish Litigation Blog, July 14, 2016.

Shmuel, JA, and Francis, TM, "Notice of Commercialization is only Effective After FDA-Approval Regardless of Whether Parties Dance," Fish Litigation Blog, July 11, 2016.

Shmuel, JA, and Francis, TM, "You Can’t Patent Dance Your Way Out of Biosimilar Notice," Law360, July 8, 2016.

Shmuel, JA, Francis, TM, and Pechette, AM, "Janssen Uses Manufacturing Info Obtained in BPCIA Litigation to Target Supplier," Fish Litigation Blog, June 17, 2016.

Shmuel, JA, Francis, TM, and Jack, SE, "Amgen v. Sandoz—The Biosimilars Battle Continues," Fish Litigation Blog, June 15, 2016. 

Shmuel, JA, Francis, TM, and Pechette, AM, "Janssen Continues BPCIA Litigation Against Celltrion But Eyes New Target," Fish Litigation Blog, June 10, 2016.

Shmuel, JA and Francis, TM, "Janssen Seeks Expedited Trial Following FDA Approval of Remicade Biosimilar," Fish Litigation Blog, April 13, 2016. 

Shmuel, JA and Francis, TM, "Biosimilar Law May Head to the Supreme Court," Fish Litigation Blog, February 17, 2016. 

Shmuel, JA and Chacon, MA, "Diagonostics Patent Eligibility: A Turning Point Approaches," Life Sciences Intellectual Property Review, February 16, 2016.

Shmuel, JA and Iwanicki, JP, "The Attack on Patentable Subject Matter: ACLU v. Myriad Genetics as a Harbinger of Things to Come," BNA Patent, Trademark & Copyright Journal, August 27, 2010.

Lichter JA, et al. "Design of antibacterial surfaces and interfaces: Polyelectrolyte multilayers as a multifunctional platform," Macromolecules, 42 (22), 8573–8586, 2009.

Hajicharalambous CH, Lichter JA, et al. "Nano- and sub-micron porous polyelectrolyte multilayer assemblies: biomimetic surfaces for human corneal epithelial cells," Biomaterials, 9 (23-24), 4029-4036, 2009.

Lichter JA and Rubner MF "Polyelectrolyte Multilayers with Intrinsic Antimicrobial Functionality: The Importance of Mobile Polycations," Langmuir, 25 (13), 686–7694, 2009.

Lichter JA, et al. "Substrata Mechanical Stiffness Can Regulate Adhesion of Viable Bacteria," Biomacromolecules, 9 (6), 1571–1578, 2008.

Thompson MT, Berg MC, Tobias IS, Lichter JA, Rubner MF, Van Vliet KJ. "Biochemical functionalization of polymeric cell substrata can alter mechanical compliance," Biomacromolecules, 7 (6), 1990-1995, 2006.

Services

What's trending with Jenny

Filter by
Fish Litigation Blog
September 27, 2016
Amgen’s Humira Biosimilar Becomes the Fourth FDA Approved Biosimilar
Amgen’s Humira Biosimilar Becomes the Fourth FDA Approved Biosimilar
Authors: Holly Chamberlain, Jenny Shmuel, Ph.D., Tasha M. Francis, Ph.D.
IP Litigation
Life Sciences
Fish Litigation Blog
September 20, 2016
Amgen Argues “Entire Balance of BPCIA” in Jeopardy unless Federal Circuit Overturns Discovery Ruling
Amgen Argues “Entire Balance of BPCIA” in Jeopardy unless Federal Circuit Overturns Discovery Ruling
Authors: Holly Chamberlain, Jenny Shmuel, Ph.D., Tasha M. Francis, Ph.D.
IP Litigation
Life Sciences
Fish Litigation Blog
September 19, 2016
The Dance Continues: Apotex Petitions the Supreme Court for Review
The Dance Continues: Apotex Petitions the Supreme Court for Review
Authors: Will Orlady, Jenny Shmuel, Ph.D., Tasha M. Francis, Ph.D.
IP Litigation
Life Sciences
Fish Litigation Blog
September 8, 2016
Amgen Loses BPCIA Suit Against Apotex’s Neulasta® and Neupogen® Biosimilars
Amgen Loses BPCIA Suit Against Apotex’s Neulasta® and Neupogen® Biosimilars
Authors: Jenny Shmuel, Ph.D., Tasha M. Francis, Ph.D.
IP Litigation
Life Sciences
Fish Litigation Blog
August 31, 2016
FDA Approves Sandoz's Biosimilar of Enbrel®
FDA Approves Sandoz's Biosimilar of Enbrel®
Authors: Jenny Shmuel, Ph.D., Tasha M. Francis, Ph.D.
IP Litigation
Life Sciences
Fish Litigation Blog
August 15, 2016
Federal Circuit Denies Motion to Dismiss Appeal of BPCIA-Related Discovery Order
Federal Circuit Denies Motion to Dismiss Appeal of BPCIA-Related Discovery Order
Author: Jenny Shmuel, Ph.D.
IP Litigation
Federal Circuit
Life Sciences
Fish Litigation Blog
August 8, 2016
Amgen Can Enforce Notice of Commercial Marketing for Epogen® Biosimilar
Amgen Can Enforce Notice of Commercial Marketing for Epogen® Biosimilar
Authors: Jenny Shmuel, Ph.D., Tasha M. Francis, Ph.D.
IP Litigation
Life Sciences
Fish Litigation Blog
July 26, 2016
Amgen DJ to Compel Patent Dance Dismissed
Amgen DJ to Compel Patent Dance Dismissed
Authors: Jenny Shmuel, Ph.D., Tasha M. Francis, Ph.D.
IP Litigation
Life Sciences
Fish Litigation Blog
July 14, 2016
Fall-Out from the Federal Circuit’s Decision in Amgen v. Apotex
Fall-Out from the Federal Circuit’s Decision in <i>Amgen v. Apotex</i>
Authors: Jenny Shmuel, Ph.D., Tasha M. Francis, Ph.D., Alex Pechette
IP Litigation
Life Sciences
Fish Litigation Blog
July 11, 2016
Notice of Commercialization Is Only Effective After FDA-Approval Regardless of Whether Parties Dance
Notice of Commercialization Is Only Effective After FDA-Approval Regardless of Whether Parties Dance
Authors: Jenny Shmuel, Ph.D., Tasha M. Francis, Ph.D.
IP Litigation
Fish Litigation Blog
June 22, 2016
Amgen v. Sandoz SCOTUS Appeal on Hold Until October
<i>Amgen v. Sandoz</i> SCOTUS Appeal on Hold Until October
Authors: Jenny Shmuel, Ph.D., Tasha M. Francis, Ph.D., Alex Pechette
IP Litigation
Life Sciences
Fish Litigation Blog
August 25, 2016
Court Invalidates Janssen Remicade® Patent for Double Patenting; Celltrion Seeks Speedy Appeal
Hot Topics Related to Biosimilars and the BPCIA
Authors: Rachel Bandli, Jenny Shmuel, Ph.D.
IP Litigation
Life Sciences
load more topics